Advokatfirmaet Thommessen AS is a key port of call for multinational and domestic clients on complex IP litigation involving patents, trade marks, and trade secrets. The firm has notable sector experience in the life sciences, oil and gas, and marine industries, and regularly advises on transactions and licensing matters requiring IP due diligence and regulatory insight. The practice is led by seasoned IP litigator Camilla Vislie, with Magnus Hauge Greaker, who has particular experience in pharmaceutical and oil-related disputes, and litigator Eirik W Raanes serving as key practitioners.

Legal 500 Editorial commentary

Accolades

Client satisfaction: Sector knowledge

Client satisfaction: NPS ®

Testimonials

Collated independently by Legal 500 research team.

‘Eirik Raanes is the perfect trusted advisor in highly strategic IP matters, providing to-the-point practical legal advice.’
‘Their knowledge of the subject is sublime.’
‘I highly recommend Magnus Hauge Greaker for intellectual property matters. He has a great team supporting him, and he excels at identifying the clearest, most successful strategy — preferring to win the essential battles rather than fight everyone. His practical, strategic approach gives confidence and delivers results.’
‘The team covers all aspects of intellectual property law and provides efficient and high-quality advice throughout the field.’
‘The team provides excellent legal advice on the spot, perfectly adapted to the Norwegian legal challenges.’

Key clients

Bristol-Myers Squibb
BioMar AS
TONO SA
Novo Nordisk AS
Equinor ASA
Vianode AS
Johnson&Johnson
Janssen
AutoStore AS
Intervet International BV
Philip Morris International
Philip Morris Norway AS

Work highlights

Represented Bristol-Myers Squibb in the appeal case against Teva relating to the patent protecting Bristol-Myers Squibb's groundbreaking drug Eliquis® (apixaban).

Represented Optime Subsea in a patent dispute against Subsea Solutions AS relating to Optime's system for intervention and work-over of subsea wells.

Represented Janssen Biotech Inc. (Johnson & Johnson) in a patent dispute relating to Janssen's patent EP'606 protecting ustekinumab for use in ulcerative colitis.